The safety of antimalarial drugs in pregnancy

• Published in: Drug safety Vol. 14; no. 3; p. 131
• Main Authors: Phillips-Howard, P A, Wood, D
• Format: Journal Article
• Language: English
• Published: New Zealand 01.03.1996
• Subjects: Animals; Anti-Infective Agents; Antimalarials - therapeutic use; Antimalarials - toxicity; Chloroquine; Contraindications; Female; Folic Acid Antagonists; Humans; Malaria - drug therapy; Pregnancy; Pregnancy Complications, Parasitic - drug therapy
• ISSN: 0114-5916
• DOI: 10.2165/00002018-199614030-00001

Alternative drugs to chloroquine are required to prevent the deleterious effects of malaria in pregnancy. Fear of potential toxicity has limited antimalarial drug use in pregnancy. Animal toxicity studies have documented teratogenicity when antimalarials are administered at high dosages. Excepting the tetracyclines, there is no evidence to suggest that, at standard dosages, any of the antimalarial drugs are teratogenic. Primaquine is not recommended because of the potential risk of haemolytic effects in the fetus. Rates of spontaneous abortion and birth defects were comparable in pregnant women taking mefloquine, compared with chloroquine-proguanil, or pyrimethamine-sulfadoxine prophylaxis, in the first trimester of pregnancy. Standard doses of quinine do not increase the risk of abortion or preterm delivery. Therapeutic mefloquine does not provoke hypoglycaemia. There is no evidence in the literature to support the hypothetical risk of kernicterus in the newborn, following exposure to antimalarial drugs containing sulphonamides or sulphones prior to delivery. Documentation of the safety of doxycycline, halofantrine, and the artemisinin derivatives in the treatment of malaria in pregnant women is currently limited.